97907947 - MURAL ONCOLOGY

Information

• Trademark
• 97907947

• Source

• Serial Number

  97907947

• International Classifications

  • 1 - Chemicals used in industry, science and photography, as well as in agriculture, horticulture and forestry
  • 5 - Pharmaceutical and veterinary preparations
  • 42 - Scientific and technological services and research and design relating thereto
  • 44 - Medical services

• Filing Date

  April 26, 2023
  a year ago

• Transaction Date

  October 28, 2024
  3 months ago

• Status Date

  October 28, 2024
  3 months ago

• Location Date

  October 28, 2024
  3 months ago

• Status Code

  653

• Current Location

  TMO LAW OFFICE 119

  Employee Name

  TANNER, MICHAEL

• Attorney Docket Number

  139079-0104

  Attorney Name

  Norm J. Rich

  Law Office Assigned Location Code

  N10

• Owners

  • ALKERMES, INC

Case File Statements

• GS0051: Biopharmaceutical active substances, namely, pharmaceutical preparations and substances for the treatment of oncological-related diseases and disorders; Biological preparations for the treatment of cancer; Engineered fusion proteins for medical diagnostic and treatment purposes, namely, engineered fusion proteins created through the use of circular permutation technology for use in the treatment of cancer and cancer-related disorders; Engineered interleukin protein pharmaceutical preparations for use in optimizing patients' immune cellular response to prevent cancer-associated morbidity and mortality; Pharmaceutical preparations, namely, tumor-targeted immunotherapeutic fusion proteins for the treatment of cancer and cancer-related disorders; Cytokine inhibitory pharmaceutical and biological preparations for use in the treatment of oncology-related diseases and disorders; Biological and chemical immunotherapy preparations comprising anti-body-cytokine fusion protein pharmaceutical preparations for use in the medical treatment and prevention of cancer
• GS0011: Therapeutic proteins for use in the manufacture of pharmaceutical preparations
• GS0441: Providing educational information in the field of medication treatment for oncology to health care providers and patients, namely, providing information in the field of cancer prevention, screening, diagnosis and treatment
• DS0000: "ONCOLOGY"
• GS0421: Research and development of medicines for use in the fields of oncology-related diseases and disorders; Protein engineering for others for use in the development of pharmaceuticals; Protein structure modifications for others for use in the development of pharmaceuticals, namely, conducting pharmaceutical research and development of engineered protein therapeutic pharmaceuticals and biopharmaceuticals for others; Conducting medical and scientific research in the fields of oncology-related diseases and disorders for others; Conducting clinical medical research for others in the field of cancerous diseases and disorders; Clinical research in the field of cancerous diseases and disorders in the nature of research and development of pharmaceuticals and biopharmaceutical products for others; Scientific research in the field of cancerous diseases and disorders in the nature of research and development of pharmaceuticals and biopharmaceutical products for others; Providing information and data about medical and scientific research and development in the fields of pharmaceuticals, biopharmaceuticals, clinical trials, therapeutic proteins, and fusion proteins, used to treat cancerous diseases and disorders; Providing websites featuring medical and scientific research information about pharmaceutical and biopharmaceutical drugs and their preparations; Cytokine engineering and cytokine research and development for use in the development of pharmaceuticals, namely, conducting pharmaceutical research, engineering and products development for others in the fields of cancer, immunopharmaceuticals for use in the treatment of cancer and engineered cytokine therapeutic pharmaceuticals and bio-pharmaceuticals for use in the treatment of cancer and cancer-related disorders; Conducting scientific research for others in the field of cytokine biology for use in pharmaceutical research and development; Scientific research and development of immune modulating proteins for others for use in the development of pharmaceuticals; Scientific research and development for others of cytokine based biopharmaceutical treatments for oncology-related diseases and disorders; Conducting protein based therapeutic medical research and pharmaceutical products development for others in the field of pharmaceuticals and biopharmaceuticals for the treatment of cancer and related diseases and disorders; Protein or cytokine based cancer immunotherapy research and development, namely, conducting pharmaceutical research and products development for others in the field of cancer; Providing educational information in the field of medication treatment for oncology to health care providers and patients, namely, providing medical and scientific research information about clinical trials featuring pharmaceutical treatments in the field of oncology

Case File Event Statements

• 5/1/2023 - a year ago

  1 - NEW APPLICATION ENTERED Type: NWAP

• 5/24/2023 - a year ago

  2 - NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Type: NWOS

• 1/23/2024 - a year ago

  3 - ASSIGNED TO EXAMINER Type: DOCK

• 1/25/2024 - a year ago

  4 - NON-FINAL ACTION WRITTEN Type: CNRT

• 1/25/2024 - a year ago

  5 - NON-FINAL ACTION E-MAILED Type: GNRT

• 1/25/2024 - a year ago

  6 - NOTIFICATION OF NON-FINAL ACTION E-MAILED Type: GNRN

• 2/28/2024 - 12 months ago

  7 - AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Type: ASGN

• 4/23/2024 - 10 months ago

  8 - TEAS RESPONSE TO OFFICE ACTION RECEIVED Type: TROA

• 9/12/2024 - 5 months ago

  11 - TEAS/EMAIL CORRESPONDENCE ENTERED Type: TEME

• 9/12/2024 - 5 months ago

  10 - CORRESPONDENCE RECEIVED IN LAW OFFICE Type: CRFA

• 9/12/2024 - 5 months ago

  9 - ASSIGNED TO LIE Type: ALIE

• 10/28/2024 - 3 months ago

  18 - NOTIFICATION OF LETTER OF SUSPENSION E-MAILED Type: GNS3

• 10/28/2024 - 3 months ago

  14 - NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED Type: GNEN

• 10/28/2024 - 3 months ago

  15 - EXAMINER'S AMENDMENT ENTERED Type: XAEC

• 10/28/2024 - 3 months ago

  12 - EXAMINERS AMENDMENT -WRITTEN Type: CNEA

• 10/28/2024 - 3 months ago

  13 - EXAMINERS AMENDMENT E-MAILED Type: GNEA

• 10/28/2024 - 3 months ago

  16 - SUSPENSION LETTER WRITTEN Type: CNSL

• 10/28/2024 - 3 months ago

  17 - LETTER OF SUSPENSION E-MAILED Type: GNSL